Results 71 to 80 of about 57,554 (268)

Different Pathways Leading to Integrase Inhibitors Resistance

Frontiers in Microbiology, 2017
Integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL), elvitegravir, or dolutegravir (DTG), are efficient antiretroviral agents used in HIV treatment in order to inhibit retroviral integration.
E. Thierry, E. Deprez, O. Delelis
semanticscholar   +1 more source

Cas9 beyond CRISPR – SUMOylation, effector‐like potential and pathogenic adaptation

The FEBS Journal, EarlyView.
This Viewpoint explores the possibility that Cas9, beyond its canonical role in CRISPR immunity, may act as a host‐modulating effector during infection by Cas9‐encoding bacteria. Such a nucleomodulin‐like function could be influenced by eukaryotic post‐translational modifications, particularly SUMOylation, with potential implications for host–pathogen ...
Umut Sahin
wiley   +1 more source

Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen

Viruses
Integrase strand transfer inhibitors (INSTI) are associated with neuropsychiatric adverse events (NPAEs). The aim of this study was to evaluate improvements in NPAEs after switching an INSTI-based regimen to darunavir/cobicistat (DRV/c) or doravirine ...
José Antonio Mata-Marín, Carina Aurora Juárez-Contreras, Mara Soraya Rodríguez-Evaristo, Olivia Concepción Martínez-Carrizales, Ericka Pompa-Mera, Alberto Chaparro Sánchez, Salma Triana-González, Ana Luz Cano-Díaz, Jesús Enrique Gaytán-Martínez   +8 more
doaj   +1 more source

HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination

Cell Death and Disease, 2017
Integrase inhibitors are a class of antiretroviral drugs used for the treatment of AIDS that target HIV integrase, an enzyme responsible for integration of viral cDNA into host genome.
Mayilaadumveettil Nishana, N. Nilavar, Rupa Kumari, Monica Pandey, S. Raghavan   +4 more
semanticscholar   +1 more source

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

HIV Medicine, EarlyView.
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
M. Gartland, X. Wang, Q. Liao, B. Li, F. Du, M. Krystal, A. R. Tenorio, A. Pierce, J. R. Castillo‐Mancilla   +8 more
wiley   +1 more source

Late diagnosis of paediatric HIV infection in high‐income countries: Lessons from the HIV Perinatal Virtual Clinic

HIV Medicine, EarlyView.
Abstract Introduction Timely diagnosis of HIV in children remains a challenge in all settings including low‐prevalence, high‐income countries (HIC). We aimed to characterize the prevalence of late diagnosis, and prior missed diagnostic opportunities among new presentations of paediatric HIV in HIC referred to an international Perinatal Virtual Clinic ...
Carolina Curto, M. Tritzali, A. Bamford, A. C. Bailey, E. G. H. Lyall, N. E. Mackie, N. Tickner, C. Foster, on behalf of the PVC   +8 more
wiley   +1 more source

Abundance of Class 1 Integron-Integrase and Sulfonamide Resistance Genes in River Water and Sediment Is Affected by Anthropogenic Pressure and Environmental Factors

Microbial Ecology, 2016
In this study, we determined the presence of class 1 integron-integrase gene in culturable heterotrophic bacteria isolated from river water and sediment sampled upstream and downstream of a wastewater treatment plant effluent discharge.
R. Koczura, J. Mokracka, A. Taraszewska, Natalia Łopacinska   +3 more
semanticscholar   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Structure and function of retroviral integrase

Nature Reviews Microbiology, 2021
G. Maertens, A. Engelman, P. Cherepanov
semanticscholar   +1 more source

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation

Journal of Virology, 2016
HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variability presents a challenge to laboratories performing genotypic resistance testing.
Soo-Yon Rhee, Kris Sankaran, V. Varghese, M. Winters, C. Hurt, J. Eron, N. Parkin, S. Holmes, M. Holodniy, R. Shafer   +9 more
semanticscholar   +1 more source